A method of performing location teaching of a robotic arm includes maneuvering an end of arm tooling of a robotic arm to a predefined position of an interface object. The robotic arm is mounted within a mounting site of a mechanical mounting structure. The interface object is positioned on a sub-system of a medication dosing system that is mounted on the mechanical mounting structure. The interface object includes an alignment feature of a known size and shape. A sensor of the end of arm tooling is engaged with the interface object. An offset between the sensor and the interface object is determined based on an interaction between the sensor and the alignment feature. A position of the end of arm tooling is incremented with respect to the interface object along at least one axis. An actual position of the interface object is determined relative to the robotic arm.

The current pandemic due to Covid-19 stresses the importance of effectively treating highly contagious and deadly infections. The described medical device is meant to help the medical community by enabling them to treat patients more effectively. The delivery mechanism focuses on the mucous membrane. It is noninvasive and easy to use by patients directly. The device is hand-held, with incorporated germicidal UVC lights. It has two chambers connected by an internal application tip. The tip connects to a removable container which can be used with the prescribed treatment/therapy, vaccine, or viral testing fluid/reagent, as needed. Due to its versatility, non-invasive nature and germicidal properties, this device supports rapid response to infectious diseases, such as COVID-19. It may also further promote the development and use of different inoculation and drug techniques and delivery systems by enabling easy administration, via the mucous membrane.

Disclosed is a container stopper (100) coupled to a container inlet (12) of a container (10) in which content is held, the container stopper comprising: a stopper body (110) that is coupled to the container inlet (12) and has, on the upper side thereof, an auxiliary space (S1) in which auxiliary content (42) having a granular structure is held; and an upper cover (120) that is coupled to the stopper body (110), forms the auxiliary space (S1) together with the stopper body (110), and covers the auxiliary space (S1).

A medication delivery device included molded cylindrical barrel having visual marks on the surface of the barrel in the axial direction, a plunger seals the distal opening of the cylindrical barrel, a molded needle hub disposed in the proximal opening of the cylindrical barrel for sealing the needle hub to the barrel. A needle is disposed in the needle hub for communicating liquids by operation of the plunger in the axial direction. The circumferential surface on the flange of the needle hub comprises a colored mark that corresponds to a characteristic of the medication delivery device or its contents.

The presently described technology provides a pill crushing system. The pill crushing system may comprise a tablet crusher, a bowl-like structure, and an elongated cylindrical weighted rod. The tablet crusher may have an open mouth, a lower end of the tablet crusher and a cap. The lower end of the tablet crusher may have a closed base provided with a peripheral thread along surface wall of the closed base. The cap may have a peripheral thread for engagement with the peripheral thread of the tablet crusher. The threaded arrangement for the tablet crusher and the cap are such as to bring the cap close to the closed base of the tablet crusher into engagement with the cap upon turning the cap in one direction, whereby a pill interposed therebetween may be crushed. The bowl-like structure may have smooth surfaces such that a residue after a pill is grounded in the bowl-like structure is less than 2 wt % of the pill. The elongated cylindrical weighted rod may have smooth surfaces at one end.

A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg/ml or 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: subjecting the AST-3424 active pharmaceutical ingredient and a partial prescription volume of ethanol to a first dissolution and formulation; adding a prescription volume of propylene glycol for a second dissolution and formulation; and then adding the remaining prescription volume of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg/ml of AST-3424 active pharmaceutical ingredient. Provided is an AST-3424 injection for injection, wherein the solvent is water, a glucose solution, ethanol, or propylene glycol, the solutes consist of the AST-3424 active pharmaceutical ingredient, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active pharmaceutical ingredient of the injection is 0.001-1.000 mg/ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

This invention relates to a method of identifying an accurate dosage of medicine in a dosage chamber of a syringe including the steps of providing an accurate dosage of a detailed single dosage medicine for insertion into a dosage chamber of a syringe; identifying the accurate dosage of medicine in the dosage chamber by retaining a notifier of the accurate dosage; securing the notifier with the syringe wherein the accurate dosage of medicine in a dosage chamber of a syringe is shown by the details on the notifier when secured with the syringe and allowing usage of the syringe to dispense the accurate dosage.

A dispenser comprises a cylinder in fluid communication with a one-way valve and an inlet in fluid communication with the cylinder. A lumen and a flow control member deliver fluid from a container to the inlet. A piston draws fluid through the flow control member and inlet into the cylinder upon movement of the piston in a first direction, and expels the fluid through the one-way valve upon movement of the piston in a second direction. The dispenser may be activated by either a “dual-action” mode of operation where an activating member is moved to retract the piston and provide the stored energy and then an-actuator is depressed to release the stored energy to the piston or a “single-action” mode of operation where an actuator is depressed in a single direction which concurrently retracts the piston, provides the stored energy and then releases the stored energy to piston.

A glass for a pharmaceutical container of the present invention contains, as a glass composition, in terms of mol %, 70% to 85% of SiO.sub.2, 3% to 13% of Al.sub.2O.sub.3, 0% to 5% of B.sub.2O.sub.3, 0.1% to 18% of Li.sub.2O+Na.sub.2O+K.sub.2O, and 0% to 10% of MgO+CaO+SrO+BaO, in which a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O)/Al.sub.2O.sub.3 is 1 or more and a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O+MgO+CaO+SrO+BaO—Al.sub.2O.sub.3)/(SiO.sub.2+Al.sub.2O.sub.3) is 0.2 or less.

A glass tube for pharmaceutical containers and a manufacturing process for a glass tube are provided. The glass tubes are characterized by a homogenous and low alkali leachability on the inner surface.